Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 68Breast 11Head & Neck 10Genitourinary 7Gastrointestinal 4CNS 3Tumor-Agnostic 2Other solid neoplasm 1Lymphoid 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Gefitinib × Tumor-Agnostic × Clear all
NCT00127829 2009-04-23

AGUS

AstraZeneca

Phase 1 Completed
66 enrolled
Tumor-Agnostic

Neoplasms

NCT00635973 2009-04-22

Open-Label Extension of Other SZ1839 (Iressa) Trials

AstraZeneca

Phase 3 Completed
100 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡